Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 BioSpaceSales of Amgen's thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025. Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amgen scores with new thyroid eye disease formulationNext: AI giant Anthropic buys Coefficient Bio for $400m Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
